[1] Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol, 2016, 39:98-106.
[2] Peeraphatdit T, Wang J,Odenwald M, et al. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation.Hepatology, 2020, 72:315-329.
[3] Abdel-Wahab N, Shah M, Lopez-Olivo MA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review immune checkpoint inhibitors in cancer and preexisting autoimmune disease. Ann Intern Med, 2018,168:121-130.
[4] Institute NC. Common terminology criteria for adverse events (CTCAE) version 4.03. In: National Cancer Institute, 2009
[5] Parlati L, Vallet-Pichard A, Batista R, et al. Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: a retrospective study. J Hepatol, 2018, 69:1396-1397.
[6] Affolter T, Llewellyn HP, Bartlett DW, et al. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS One, 2019,14:e0217276
[7] Alessandrino F, Tirumani SH, Krajewski KM,et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol, 2017, 72:521-533.
[8] Danan G, Teschke R. RUCAM in drug and herb induced liver injury: The Update. Int J Mol Sci, 2015,17:14..
[9] Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Journal for immunotherapy of cancer, 2017, 5:95.Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol, 2018, 31:965-973.
[10] Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, Version 1.2019. J Natl Compr Canc Netw, 2019, 17:255-289
[11] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 2018,69(1):182-236.
[12] Ziemer M, Koukoulioti E, Beyer S, et al. Managing immune checkpoint-inhibitor induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol, 2017, 66:657-659.
[13] Haque T, Sasatomi E, Hayashi PH. Drug-induced liver injury: pattern recognition and future directions. Gut Liver, 2016, 10(1):27-36.
[14] De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol, 2018, 68: 1181-1190. |
